Guggenheim raises Genmab price target to $58, keeps Buy
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab to $58 from $54 and kept a Buy rating and Top Pick status.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.